TSE:PMN ProMIS Neurosciences (PMN) Stock Price, News & Analysis C$6.00 -0.24 (-3.85%) (As of 07/21/2023) Add Compare Share Share Stock Analysis Stock Analysis About ProMIS Neurosciences Stock (TSE:PMN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ProMIS Neurosciences alerts:Sign Up Key Stats Today's RangeC$5.98▼C$6.4950-Day RangeC$6.00▼C$6.0052-Week RangeC$3.34▼C$11.10Volume19,701 shsAverage Volume3,327 shsMarket CapitalizationC$51.48 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.Read More… 626 winning trades out of 647… (Ad)Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trader has done over the past 8 years—closing 647 trades, with an unbelievable 97% win rate. Now, for the first time, he's breaking his silence and revealing his personal technique for success.Click here to watch our exclusive interview and uncover his personal technique Receive PMN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProMIS Neurosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address PMN Stock News HeadlinesProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer’s Disease ConferenceOctober 30, 2024 | finance.yahoo.comProMIS Neurosciences, Inc. (PMN): Analysts Are Bullish On This Undervalued Canadian Stock NowOctober 13, 2024 | msn.comBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.November 5, 2024 | Brownstone Research (Ad)Targeting brain lesions with TMS shows promise in treating PTSD in veteransSeptember 27, 2024 | msn.comProMIS Neurosciences Inc.: ProMIS Neurosciences Announces Second Quarter 2024 Financial Results and Recent HighlightsAugust 9, 2024 | finanznachrichten.deBuy Rating on ProMIS Neurosciences Backed by Innovative Alzheimer’s Treatment and Strong FinancialsAugust 9, 2024 | markets.businessinsider.comAnaergia: Top 10 Undervalued Growth Stocks on TSX (ANRG)July 27, 2024 | theglobeandmail.comPMN Stock Earnings: ProMIS Neurosciences Beats EPS for Q4 2023April 1, 2024 | msn.comSee More Headlines PMN Stock Analysis - Frequently Asked Questions How have PMN shares performed this year? ProMIS Neurosciences' stock was trading at C$6.00 at the beginning of the year. Since then, PMN stock has increased by 0.0% and is now trading at C$6.00. View the best growth stocks for 2024 here. How do I buy shares of ProMIS Neurosciences? Shares of PMN stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. What other stocks do shareholders of ProMIS Neurosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that ProMIS Neurosciences investors own include CRISPR Therapeutics (CRSP), Aurora Cannabis (ACB), Keurig Dr Pepper (KDP), Biocept (BIOC), Onconova Therapeutics (ONTX), Spectra7 Microsystems (SEV) and TherapeuticsMD (TXMD). Industry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolTSE:PMN Previous SymbolTSE:AMF CUSIPN/A CIKN/A Webwww.promisneurosciences.com Phone+1-416-8476898FaxN/AEmployees6Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($3.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-20,930,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-837.71% Return on Assets-168.33% Debt Debt-to-Equity Ratio108.33 Current Ratio0.51 Quick Ratio1.30 Sales & Book Value Annual SalesC$7,558.00 Price / Sales6,811.33 Cash FlowC$0.43 per share Price / Cash Flow14.07 Book ValueC($0.72) per share Price / Book-8.33Miscellaneous Outstanding Shares8,580,000Free FloatN/AMarket CapC$51.48 million OptionableNot Optionable Beta1.19 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (TSE:PMN) was last updated on 11/5/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Crypto 101 Media | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProMIS Neurosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProMIS Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.